Dyne Therapeutics Presents Preclinical Data from its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
June 25, 2021 07:30 ET
|
Dyne Therapeutics, Inc.
- FORCE™ platform enables targeted muscle delivery with lead FSHD program candidate demonstrating potent suppression of DUX4 biomarkers in patient cell line - WALTHAM, Mass., June 25, 2021 (GLOBE...
Dyne Therapeutics Announces Chief Scientific Officer Transition
June 02, 2021 16:05 ET
|
Dyne Therapeutics, Inc.
- Co-founder Romesh Subramanian, Ph.D., stepping down as chief scientific officer and will serve as an advisor after leading successful R&D and pipeline-building efforts - - Oxana Beskrovnaya,...
Dyne Therapeutics to Present at Jefferies Virtual Healthcare Conference
May 26, 2021 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with...
Dyne Therapeutics Presents New Preclinical Data from its Myotonic Dystrophy Type 1 Program During American Society of Gene & Cell Therapy Annual Meeting Demonstrating Sustained Knockdown of Toxic Human Nuclear DMPK RNA
May 14, 2021 07:00 ET
|
Dyne Therapeutics, Inc.
- Robust Reduction in DMPK RNA in Multiple Muscles at Four Weeks in Novel In Vivo Model Developed by Dyne; Additional In Vitro Data Support Advancement of Lead DM1 Candidate - - DM1 Program One of...
Dyne Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
May 06, 2021 07:29 ET
|
Dyne Therapeutics, Inc.
- On Track to Submit INDs for DM1, DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 - - Well-Resourced with Cash Runway Expected into the Second Half of 2024 - ...
New Preclinical Data from Dyne Therapeutics’ Myotonic Dystrophy Type 1 Program to be Featured in Presentations During Upcoming American Society of Gene & Cell Therapy Annual Meeting
April 27, 2021 16:35 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living...
Dyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
March 04, 2021 07:35 ET
|
Dyne Therapeutics, Inc.
- Preclinical Data Further Validate FORCE™ Platform; Driving Toward IND Submissions for DM1, DMD and FSHD Programs Between Q4’21 and Q4’22 - - Recent Appointments to Experienced Leadership Team...
Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer
March 04, 2021 07:25 ET
|
Dyne Therapeutics, Inc.
Seasoned Clinical Leader Brings Deep Experience in Drug Development, Including Approval of an Oligonucleotide Therapy in Neuromuscular Disease WALTHAM, Mass., March 04, 2021 (GLOBE NEWSWIRE) --...
Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs
February 08, 2021 07:30 ET
|
Dyne Therapeutics, Inc.
Dr. Dugar Brings Over 20 Years of Experience in Medical Affairs, Clinical and Commercial Development, and Real-World Evidence, Including in Rare Muscle Disease WALTHAM, Mass., Feb. 08, 2021 (GLOBE...
Dyne Therapeutics Announces Pricing of $168 Million Public Offering
January 20, 2021 20:05 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living...